These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37342584)

  • 1. A case of acute myocarditis induced by PD-1 inhibitor (sintilimab) in the treatment of large cell neuroendocrine carcinoma.
    Zheng S; Zhang H; Hu B; Zhou J; Wen L; Li M
    Heliyon; 2023 Jun; 9(6):e16874. PubMed ID: 37342584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sintilimab plus chemotherapy for first-line treatment of advanced or metastatic nonsquamous non-small-cell lung cancer: network meta-analysis.
    Molife C; Brnabic A; Stefaniak VJ; Belger MA; Gruver K; Chen JV; Souri S; Blumenschein GR
    Immunotherapy; 2023 Mar; 15(4):293-309. PubMed ID: 36748406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
    Gu YC; Liu Y; Xie C; Cao BS
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint inhibitor-induced myocarditis in lung cancer patients: a case report of sintilimab-induced myocarditis and a review of the literature.
    Bi H; Ren D; Wang Q; Ding X; Wang H
    Ann Palliat Med; 2021 Jan; 10(1):793-802. PubMed ID: 33545801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sintilimab-Induced Myocarditis in a Patient with Gastric Cancer: A Case Report and Literature Review.
    Liu X; Zeng Z; Cao J; Li X; Muhetaer M; Jin Z; Cai H; Lu Z
    J Cardiovasc Dev Dis; 2023 Oct; 10(10):. PubMed ID: 37887869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case of subclinical immune checkpoint inhibitor-associated myocarditis in non-small cell lung cancer.
    Hu Y; Liu C; Jin S; Yi Z; Wang C; Pan X; Huang H
    BMC Pulm Med; 2023 Apr; 23(1):119. PubMed ID: 37060029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myocarditis and myositis/myasthenia gravis overlap syndrome induced by immune checkpoint inhibitor followed by esophageal hiatal hernia: A case report and review of the literature.
    Yin B; Xiao J; Wang X; Li X; Guan Y; Chen J; Han P; Li K; Wang J
    Front Med (Lausanne); 2022; 9():950801. PubMed ID: 36457566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report.
    Monge C; Maeng H; Brofferio A; Apolo AB; Sathya B; Arai AE; Gulley JL; Bilusic M
    J Immunother Cancer; 2018 Dec; 6(1):150. PubMed ID: 30563577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kikuchi disease: A case report about Sintilimab-induced Kikuchi histiocytic necrotizing lymphadenitis and literature review.
    Ren C; Wang Y; Yang X; Tuo Y; Li Y; Gong J
    Heliyon; 2024 May; 10(9):e30608. PubMed ID: 38742085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial.
    Lu S; Wu L; Jian H; Chen Y; Wang Q; Fang J; Wang Z; Hu Y; Sun M; Han L; Miao L; Ding C; Cui J; Li B; Pan Y; Li X; Ye F; Liu A; Wang K; Cang S; Zhou H; Sun X; Ferry D; Lin Y; Wang S; Zhang W; Zhang C
    Lancet Oncol; 2022 Sep; 23(9):1167-1179. PubMed ID: 35908558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indirect comparison of sintilimab and other PD-L1 inhibitors for first-line treatment of non-squamous non-small-cell lung cancer.
    Zhang L; Qian Y; Li J; Cui C; Chen L; Qu S; Lu S
    Future Oncol; 2022 May; 18(15):1896-1905. PubMed ID: 35311347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolated adrenocorticotropic hormone deficiency associated with sintilimab therapy in a patient with advanced lung adenocarcinoma: a case report and literature review.
    Lin SH; Zhang A; Li LZ; Zhao LC; Wu LX; Fang CT
    BMC Endocr Disord; 2022 Sep; 22(1):239. PubMed ID: 36153581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Fatal Case of Myocarditis Following Myositis Induced by Pembrolizumab Treatment for Metastatic Upper Urinary Tract Urothelial Carcinoma.
    Matsui H; Kawai T; Sato Y; Ishida J; Kadowaki H; Akiyama Y; Yamada Y; Nakamura M; Yamada D; Akazawa H; Suzuki M; Komuro I; Kume H
    Int Heart J; 2020 Sep; 61(5):1070-1074. PubMed ID: 32921673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upper Gastrointestinal Tract IrAEs: A Case Report About Sintilimab-Induced Acute Erosive Hemorrhagic Gastritis.
    Ai Q; Chen W; Li Y; Li G
    Front Immunol; 2022; 13():840916. PubMed ID: 35720298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sintilimab induced ICIAM in the treatment of advanced HCC: A case report and analysis of research progress.
    Ji H; Wen Z; Liu B; Chen H; Lin Q; Chen Z
    Front Immunol; 2022; 13():995121. PubMed ID: 36091070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myositis-myasthenia gravis overlap syndrome complicated with myasthenia crisis and myocarditis associated with anti-programmed cell death-1 (sintilimab) therapy for lung adenocarcinoma.
    Xing Q; Zhang ZW; Lin QH; Shen LH; Wang PM; Zhang S; Fan M; Zhu B
    Ann Transl Med; 2020 Mar; 8(5):250. PubMed ID: 32309397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of first-line versus second-line use of domestic anti-PD-1 antibody sintilimab in Chinese patients with advanced or metastatic squamous non-small cell lung cancer.
    Cheng R; Zhou Z; Liu Q
    Cancer Med; 2023 Mar; 12(6):7389-7397. PubMed ID: 36373001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Corneal ulcer development due to sintilimab-anlotinib combination therapy-induced dry eye: a case report.
    Xiang X; Lin W; Guan X; Zhou B; Yuan Y; Silva D; Wang Y
    Transl Cancer Res; 2024 May; 13(5):2571-2579. PubMed ID: 38881937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
    Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
    J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase IB Trial of Autologous Cytokine-Induced Killer Cells in Combination with Sintilimab, Monoclonal Antibody Against Programmed Cell Death-1, plus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.
    Zhou L; Xiong Y; Wang Y; Meng Y; Zhang W; Shen M; Zhang X; Li S; Ren B; Li R; Han Y; Zhang J; Cao S; Du W; Sun Q; Wei F; An X; Yang L; Zhang Y; Ma W; Xu W; Zhang Y; Jiang J; Xu X; Xia J; Liu L; Ren X
    Clin Lung Cancer; 2022 Dec; 23(8):709-719. PubMed ID: 35995696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.